AI Summary
This article discusses the need for a tissue-agnostic genome-wide methylome enrichment MRD assay for detecting molecular residual disease in patients with head and neck malignancies. The test is crucial for identifying patients at risk of recurrence within the first two years after treatment, as outcomes for head and neck cancer patients remain poor despite curative treatment. The assay aims to cater to both HPV-positive and HPV-negative patients, where tissue samples are often limited. This research has potential implications for improving survival rates and personalized treatment approaches for HNC patients.
Outcomes for patients with locally advanced head and neck cancer (HNC) treated with curative intent remain disappointing, with 5-year survival rates at 50%. Most recurrences occur within the first two years after treatment, providing a window of opportunity to identify patients with molecular residual disease (MRD). A tissue agnostic test for MRD detection in HNC, where tissue is often scarce, and suitable for HPV-positive and HPV-negative patients, is needed.